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ABSTRACT
The role of long non-coding RNAs (lncRNAs) in regu-
lating endothelial function through the DNA damage
response (DDR) remains poorly understood. In this
study, we demonstrate that lncRNA maternally ex-
pressed gene 3 (Meg3) interacts with the RNA bind-
ing protein polypyrimidine tract binding protein 3
(PTBP3) to regulate gene expression and endothelial
function through p53 signaling a major coordinator
of apoptosis and cell proliferation triggered by the
DDR. Meg3 expression is induced in endothelial cells
(ECs) upon p53 activation. Meg3 silencing induces
DNA damage, activates p53 signaling, increases the
expression of p53 target genes, promotes EC apop-
tosis, and inhibits EC proliferation. Mechanistically,
Meg3 silencing reduces the interaction of p53 with
Mdm2, induces p53 expression, and promotes the
association of p53 with the promoters of a subset
of p53 target genes. PTBP3 silencing recapitulates
the effects of Meg3 deficiency on the expression of
p53 target genes, EC apoptosis and proliferation. The
Meg3-dependent association of PTBP3 with the pro-
moters of p53 target genes suggests that Meg3 and
PTBP3 restrain p53 activation. Our studies reveal
a novel role of Meg3 and PTBP3 in regulating p53
signaling and endothelial function, which may serve
as novel targets for therapies to restore endothelial
homeostasis.
INTRODUCTION
The vascular endothelium plays an important role in main-
taining the proper functions of different organs. Endothe-
lial dysfunction contributes to the pathogenesis of major
chronic diseases such as obesity, diabetes and atheroscle-
rosis (1–4). Different insults, such as chronic inflamma-
tory disease states, oxidative stress, metabolic dysfunction
and aging, promote endothelial dysfunction through tran-
scriptional reprogramming (5–8). In response to these in-
sults, DNA damage may ensue and adversely contribute to
cardiovascular and metabolic disease (9–12). However, the
molecular mechanisms and signaling events by which DNA
damage regulates endothelial function are not completely
understood.
The cellular response to DNA damage involves the ac-
tivation of multiple signaling cascades that orchestrate
the appropriate repair of DNA damage with signaling
events involved in apoptosis and proliferation (13,14).
The DNA damage response (DDR) resulting from geno-
toxic, oxidative, and metabolic stress is controlled by three
phosphoinositide 3-kinase (PI3K)-related kinases: Ataxia-
telangiectasia mutated (ATM), ATM- and Rad3-related
(ATR), and DNA-dependent protein kinase (DNA-PK)
(12,13). Formation of DNA double-strand breaks (DSB) is
a severe type of DNA damage. ATM is vigorously activated
following DSB and interacts with many downstream effec-
tors including p53 (14). p53 protein is a stress- and DNA
damage-responsive transcriptional factor that activates cell
cycle arrest, DNA repair, and apoptosis (15). High glucose
or palmitic acid induces p53 expression in human endothe-
lial cells (ECs) (16). Expression of p53 is also induced in
*To whom correspondence should be addressed. Tel: +1 402 472 8898; Fax: +1 402 472 7842; Email: xsun17@unl.edu
Correspondence may also be addressed to Mark W. Feinberg. Tel: +1 617 525 4381; Fax: +1 617 525 4380; Email: mfeinberg@bwh.harvard.edu
†The authors wish it to be known that, in their opinion, the first two authors should be regarded as Joint First Authors.
C© The Author(s) 2018. Published by Oxford University Press on behalf of Nucleic Acids Research.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License
(http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work
is properly cited. For commercial re-use, please contact journals.permissions@oup.com
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/47/3/1505/5198489 by U
niversity of N
ebraska-Lincoln Libraries user on 02 O
ctober 2019
1506 Nucleic Acids Research, 2019, Vol. 47, No. 3
vascular endothelium in mice fed a high-calorie diet (16).
Inhibition of endothelial p53 attenuated metabolic abnor-
malities associated with dietary obesity (16). Deletion of
p53 in the vascular endothelium reduced the number of
apoptotic ECs in mice, and protects mice from cardiac dys-
function after pressure overload (17). Therefore, discover-
ing new mechanisms by which p53 signaling regulates en-
dothelial function may provide new targets for therapeutic
intervention.
Long non-coding RNAs (lncRNAs) are an important
class of RNA transcripts that regulate gene expression and
signal transduction. Changes in their expression and func-
tion contribute to the pathogenesis of a range of disease
states (18–21). LncRNAs participate in several aspects of
the DDR and regulate the expression of key components
of related pathways (22,23). LncRNAmaternally expressed
gene 3 (Meg3) is an imprinted gene located at chromosome
12 in mice and chromosome 14 in humans (24). The role
of Meg3 has been examined in different cell types including
cancer cells, neurons, hepatocytes, cardiac fibroblasts, and
ECs (25–30). Meg3 regulates p53 signaling in a cell-specific
manner. Meg3 interacts with p53 in cancer cells and neu-
rons to activate p53-mediated inhibition of cell proliferation
and induction of apoptosis (25,27,28). In contrast,Meg3 in-
teracts with p53 in cardiac fibroblasts exerting no effects on
a p53 response, cell apoptosis, or proliferation (26). These
studies also highlight that Meg3 may regulate p53 signal-
ing in a cell-specific manner. However, it remains unknown
howMeg3 determines the transcriptional output of p53 sig-
naling in the regulation of EC proliferation and apopto-
sis in response to DNA damage. Moreover, the reciprocal
regulation of Meg3 and DNA damage remains poorly un-
derstood. In this study, we find that Meg3 cooperates with
polypyrimidine tract binding protein 3 (PTBP3) to control
the DDR, thereby protecting endothelial function.
MATERIALS AND METHODS
Reagents
Nutlin-3 and doxorubicin were purchased from Sigma (St
Louis, MO, USA). Palmitic acids were purchased fromNu-
Chek Prep, Inc. (Waterville, MN, USA). Albumin (bovine
serum, fraction v, fatty acid-poor, endotoxin-free) was pur-
chased fromEMDMillipore (Burlington,MA,USA).Gap-
meR Meg3 (5′-GTAAGACAAGCAAGAG-3′) and Gap-
meR negative control A (5′-AACACGTCTATACGC-3′)
were purchased from Exiqon (Vedbaek, Denmark). Si-
lencer™ Select Negative Control No. 1 siRNA, PTBP1
siRNA (Assay ID: s11435), and PTBP3 siRNA (Assay
ID: s19414) were purchased from Thermo Fisher Scientific
Life Sciences (Waltham, MA, USA). Recombinant human
TNF- was purchased from R&D Systems (210-TA/CF;
Minneapolis, MN, USA). Lipofectamine 2000 and TRI-
zol reagents were from Thermo Fisher Scientific Life Sci-
ences. Protease inhibitor cocktail tablets were from Roche
(Basel, Switzerland). Phosphatase inhibitor was from Ac-
tiveMotif (Carlsbad, CA,USA). ATM inhibitorKU-55933
(Cat# 118500) were fromMilliporeSigma (Burlington,MA,
USA).
Cell culture and transfection
Human Umbilical Vein Cells (HUVECs) (cc-2159) were
obtained from Lonza (Morristown, NJ, USA) and cul-
tured in EC growth medium EGM-2 (cc-3162). Cells used
for all experiments were subcultured <8 times. HUVECs
(90 000/well) were plated into 12-well plates, transfected
with 10 nM GapmeR, or 30 nM small interfering RNAs
(siRNAs) when cells reached 80–90% confluency. Lipofec-
tamine 2000 was used following the manufacturer instruc-
tions. Cells were grown for 36 h before treatment with TNF-
 (10 ng/ml), nutlin-3 (10 M), doxorubicin (0.2, 0.6 or 2.0
M), or palmitic acid (100 M) for different time points.
Palmitic acid/BSA complexes were prepared as previously
described (31). In one experiment, cells were treated with
ATM inhibitor at 10 M for 3 h.
Lentivirus production and cell transduction
pLKO.1-TRC cloning vector was a gift from Dr David
Root (Addgene plasmid #10878) (32). pMD2.G was a
gift from Dr Didier Trono (Addgene plasmid #12259).
psPAX2was a gift fromDrDidier Trono (Addgene plasmid
#12260). shp53 pLKO.1 puro was a gift fromDr BobWein-
berg (Addgene plasmid #19119) (33). Meg3 shRNA oligos
or negative control oligos were cloned into pLKO.1-TRC
cloning vector betweenAgeI and EcoRI sites. Lentivirus for
pLKO.1-ctl shRNA or pLKO.1-Meg3 shRNA was gener-
ated by cotransfection of 293T cells (ATCC CRL-3216) us-
ing pMD2.G and psPAX2 in a 3:2:1 ratio, respectively. Plas-
mids were transfected using Lipofectamine 2000. Transfec-
tion mix was added dropwise to the dish and the medium
was changed ∼16 h later. Supernatant was collected 2 days
later by filtering through a 0.45 m filter and stored at
−80◦C. Transduction of HUVECs was carried out in 6-well
plates adding 1 ml lentiviral supernatant to 1 ml medium in
combination with 8 g/ml PolybreneTM (AB01643; Amer-
ican Bio, Natick, MA, USA). The medium was changed 16
h later.
Neutral comet assay
HUVECs transfected with GapmeRs or siRNA were fur-
ther treated with or without TNF- (10 ng/ml) for 16 h.
Neutral comet assay was performed according to the man-
ufacturer’s protocol using the Single Cell Gel Electrophore-
sis kit (Enzo Life Sciences Inc. Farmingdale NY, USA).
Briefly, the cells were trypsinized, washed and resuspended
in ice-cold phosphate-buffered saline. Further, the cells were
combined with low melting point agarose and applied on
pre-coated comet slides to solidify. After cell lysis and al-
kaline denaturation for 40 min, electrophoresis was per-
formed at 15 volts (1 volt per cm) for 20 min in 1× TBE,
pH 10.0 buffer. Subsequently, the slides were dehydrated
by immersing in 70% ethanol, air-dried and stained with
CYGREEN® green dye. DNA strand break was assessed
bymeasuring tail moment and tail length using fluorescence
microscope for at least 150 comets per condition for each
experiment. Comets were analyzed using OpenComet soft-
ware.
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Transcriptomic analysis by microarray
Arraystar Human LncRNA Microarray v4.0, performed
by Arraystar Inc. (Rockville, MD, USA), is designed for
the global expression profiling of 40 173 human lncRNA
and 20,730 protein-coding mRNA transcripts. HUVECs
were transfected with 10 nM control GapmeRs or Meg3
GapmeRs and treated with 10 ng/ml TNF- for 3 h. Cells
were lysed with TRIzol reagent and total RNA was iso-
lated according to the manufacturer instructions. Sample-
labeling and array hybridization were performed accord-
ing to the Agilent One-Color Microarray-Based Gene
Expression Analysis protocol (Agilent Technology, Santa
Clara, CA, USA) with minor modifications. Briefly, mRNA
was purified from total RNA after removal of rRNA
(mRNA-ONLY™ Eukaryotic mRNA Isolation Kit, Epi-
centre, Madison WI, USA). Then, each sample was ampli-
fied and transcribed into fluorescent cRNA along the en-
tire length of the transcripts without 3′ bias utilizing a ran-
dom priming method (Arraystar Flash RNA Labeling Kit,
Arraystar, Rockville, MD, USA). The labeled cRNAs were
purified by RNeasy Mini Kit (Qiagen, Hilden, Germany).
The concentration and specific activity of the labeled cR-
NAs (pmol Cy3/g cRNA) were measured using a Nan-
oDrop™ ND-1000. 1 g of each labeled cRNA was frag-
mented by adding 5l 10×Blocking Agent and 1l of 25×
Fragmentation Buffer, then heated at 60◦C for 30 min. Fi-
nally, 25l 2×GEHybridization buffer was added to dilute
the labeled cRNA. 50 l of hybridization solution was dis-
pensed into the gasket slide and assembled into the lncRNA
expression microarray slide. The slides were incubated for
17 h at 65◦C in an Agilent Hybridization Oven. The hy-
bridized arrays were washed, fixed and scanned using the
Agilent DNAMicroarray Scanner (part number G2505C).
Agilent Feature Extraction software (version 11.0.1.1) was
used to analyze acquired array images. Quantile normaliza-
tion and subsequent data processing were performed using
the GeneSpring GX v12.1 software package (Agilent Tech-
nologies).
The predicted target genes above were input into the
Database forAnnotation, Visualization and IntegratedDis-
covery (DAVIDv6.8; https://david.ncifcrf.gov/) for pathway
analysis.We used theKEGG (KyotoEncyclopedia ofGenes
and Genomes) database to analyze the potential functions
of these target genes in the pathways (34,35). Values of P<
0.05 were considered to be statistically significant; with the
lower P values indicating greater significance of the path-
way.
Proteomic analysis using TMT10-plex labeling and liquid
chromatography-tandem mass spectrometry (LC-MS/MS)
HUVECs were transfected with 10 nM control GapmeRs
or Meg3 GapmeRs and treated with or without 10 ng/ml
TNF- for 4 h. Cells were washed 6 times with ice-cold 1×
PBS. Then cells were scraped into ice-cold 1× PBS and spun
at 300 × g for 5 min. Cell pellets were extracted for 20 min
on ice using RIPA buffer (ThermoFisher) containing 1×
protease inhibitor (EDTA-free Protease Inhibitor Cocktail,
Sigma). Protein was precipitated and washed to remove de-
tergent using the ProteoExtract kit (EMD-MilliPore). Pel-
lets were then redissolved, the protein content assayed and
50g from each sample were reducedwith 10mMDTTand
alkylated with 20 mM iodoacetamide. The proteins were di-
gested with 1 g of trypsin for 16 h at 37◦C, before addi-
tion of a further 0.5 g of trypsin for a further 6 h. The
peptides were labeled using the TMT10-plex reagent (Ther-
moFisher) according to the manufacturer’s instructions.
The three biological replicates for control samples treated
with TNF- were labeled with the 129N, 130N and 131 la-
bels. The 3 biological replicates for the Meg3 knockdown
treated with TNF- were labeled with the 126, 127N and
128N labels. Finally, two biological replicates of the con-
trol and Meg3 knockdown cells without TNF- treatment,
were labeled with the 128C, 129C and 127C, 130C labels, re-
spectively. All labeled samples were combined equally and
the mixture was fractionated into 60 fractions using high-
pH reverse phase chromatography and recombined to give
a total of 12 final fractions according to the strategy of
Yang et al. (36). Mass spectrometric analysis of each frac-
tion was carried out using aDionexU3000 nanoRSLC run-
ning a 2 h gradient through a 0.075 mm× 250 mmC18Wa-
ters CSH130 peptide column feeding into a Q-Exactive HF
mass spectrometer (ThermoScientific).
The protein identification and quantification were pro-
cessed using Mascot Server software (Matrix Science, Lon-
don, UK; version 2.5.1) and Proteome Discoverer (Ther-
moScientific, version 2.1), respectively. The mass spec-
tra were searched against the common contaminants
cRAP 20150130 database (www.theGPM.org) and the
SwissProt database (selected for Human, April 2017) us-
ing trypsin, a fragment ion mass tolerance of 0.02 Da and
a parent ion tolerance of 10 ppm. The TMT label was spec-
ified as a fixed modification for both the N-terminus and
the lysine sidechain, with oxidation of methionine and car-
bamidomethyl of cysteine specified as variable modifica-
tions. The data were searched using a decoy database to
set the false discovery rate to 1% (high confidence) and 5%
(medium confidence). The co-isolation threshold was set to
50%, and the average S/N to 10. Protein abundances were
normalized using the total abundance from all the channels.
Differentially expressed proteins were selected if theP-value
was <0.05 and the change >20%.
RNA immunoprecipitation
HUVECs were cross-linked with 0.3% formaldehyde at
room temperature for 10 min and neutralized with 0.125
M of glycine at room temperature for 5 min. Cross-linked
cells were washed with 1× PBS, collected by scraping and
lysed in polysome lysis buffer containing 100 mM KCl, 5
mMMgCl2, 10 mMHEPES at pH 7.0, 0.5%Nonidet P-40,
1 mM dithiothreitol (DTT), 200 units/ml RNase OUT (In-
vitrogen Cat. No. 10777-019) and Complete Mini, EDTA-
free Protease Inhibitor Tablet (11836170001, Roche) for 30
min on ice. Lysate was diluted to 1 ml in NT-2 buffer con-
taining 50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1 mM
MgCl2, 0.5% NP-40, 20 mM EDTA at pH 8.0, 1 mM
DTT, 200 units/ml RNase OUT and sonicated for 20 s at
20% power using Branson 250 Ultrasonic Sonifier. Lysates
were cleared by centrifugation at 10 000 × g at 4◦C for
10 min. Cleared lysates were split equally, incubated with
control Isotype IgG or PTBP3 antibody pre-coupled to
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Dynabeads™ Protein G and tumbled at 4◦C for 12 h. The
immuno-complex was washed twice with NT-2 buffer and
subsequently with NT-2 buffer supplemented with 500 mM
NaCl. Washed complex was resuspended in 150 l of 1×
NT-2 buffer supplemented with 1% sodium dodecyl sulfate
(SDS) and 1.2 mg/ml proteinase K and incubated at 55◦C
for 30 min. RNA was extracted using the TRIzol reagent.
RNA was reverse-transcribed using Superscript II reverse
transcriptase. Quantitative PCR was performed to measure
the amount of lncRNA Meg3 and the results represent the
percentage ofMeg3 in the PTBP3 interacting RNA fraction
over that of input.
Caspase3/7 activity assay
HUVECs transfected with GapmeRs or siRNAs were fur-
ther treated with or without TNF- (10 ng/ml) for 16 h.
Caspase 3/7 activity wasmeasured using caspase-Glo® 3/7
assay kit (Promega, Madison, WI, USA) according to the
manufacturer’s instructions. Relative luminescence inten-
sity was recorded using a fluorometric plate reader (BioTek
Instruments, Winooski, VT, USA).
Terminal deoxynucleotidyl transferase dUTP nick end label-
ing (TUNEL)
HUVECs transfected with GapmeRs or siRNAs were fur-
ther treated with or without TNF- (10 ng/ml) for 16 h.
TUNEL staining was performed according to the man-
ufacturer’s protocol using In Situ Cell Death Detection
Kit, TMR red (Sigma). Briefly, the cells were fixed with
4% paraformaldehyde for 30 min at room temperature
and subsequently permeabilized with 0.25% Triton X-100
in 0.1% sodium citrate for 5 min. Subsequently, the cells
were stainedwith TUNELEnzyme-TMR labelmixture and
counter stained with DAPI. Cells were analyzed by using
a fluorescent microscope (EVOS) with appropriate filters.
The numbers of TUNEL positive cells in eight random
fields were counted, the results were represented as the aver-
age number of TUNEL positive cells per High Power Field
(HPF).
EdU incorporation
HUVECs were seeded into 12-well plates (1 × 105
cells/well) 24 h prior to transfection with either control or
Meg3GapmeR. After 24 h transfection, cells were re-plated
(8 × 104/ml) and cultured for 12 h in an incubator with
5% CO2 at 37◦C. Then cells were treated with or without
TNF- (10 ng/ml) for 12 h, and EdU labeling was per-
formed using Click-iT™ EdU Alexa Fluor™ 555 Imaging
Kit (Thermo Fisher Scientific, Waltham, MA, USA). The
media was replaced with medium containing 10 M EdU
and incubated for 1.5 h in an incubator with 5% CO2 at
37◦C, followed by fixation, permeabilization, EdU detec-
tion and DNA staining according to the manufacturer’s in-
structions. Stained cells were photographed using a fluores-
cent microscope (EVOS) with 10× magnification.
Real-time qPCR
HUVECs were lysed with TRIzol reagent and total RNA
was isolated according to manufacturer instructions. High-
Capacity cDNA Reverse Transcription Kit Cat# 4368814
fromThermoFisher Scientificwas used to generate cDNAs.
GoTaq qPCR Master Mix (Cat# A6001) from Promega
was used for real-time quantitative PCR (qPCR) with
Bio-Rad CFX96 Touch Real-time PCR Detection Sys-
tem. To detect Meg3, GoTaq® Probe qPCR Master Mix
(Promega) and TaqMan® Gene Expression Assays (ID#
Hs00292028 m1) were used. See Supplementary Table S7
for primer sequences.
Cell cycle analysis
HUVECs were seeded into 6-well plates (3× 105 cells/well)
24 h prior to transfection with either control or Meg3 Gap-
meR. The medium was replaced 24 h after transfection and
the cells were cultured for another 24 h. EdU incorpora-
tion and DNA staining were performed according to the
manufacturer’s instructions of Click-iT EdU Alexa Fluor
488 flow cytometry assay Kit. The cells were incubated in
medium with 10 M EdU for 1.5 h with 5% CO2 at 37◦C.
Before fixation for 15 min at RT, the cells were trypsinized,
harvested by putting 1× 106 cells per tube and washed once
with PBS containing 1% BSA. Then the cells were perme-
abilized and stained with Click-iT reaction cocktail, DNA
was stained with FxCycle violet. Cell cycle was analyzed on
a BD Cytek FACSort.
LncRNA pull-down assay and mass spectrometry
Meg3 and its deletion mutants (primers are listed in Sup-
plementary Table S7) were cloned into pGEM-3Zf(+)
(Promega). Linearized pGEM-3Zf(+) expressing Meg3 or
Meg3 deletion mutants was used as a template to syn-
thesize biotinylated Meg3 or Meg3 antisense (AS) control
RNA using Riboprobe® In Vitro Transcription Systems
(Promega). A lncRNA pull-down assay was performed as
previously described (37). Twenty-million cells were har-
vested and lysed in 5 ml cell swelling buffer (20 mMTris–Cl,
pH 7.4, 1.5 mM MgCl2, 10 mM KCl, 0.5% NP-40, 1 mM
DTT) on ice for 30 min followed by dounce homogenizing
20 times to release nuclei. The nuclei pellet was lysed in 2
ml nuclear lysis buffer – NLB buffer (50 mM Tris–Cl, pH
8.0, 140 mM NaCl, 1 mM EDTA, 1% Triton-X100, 0.1%
sodium deoxycholate, 0.05% SDS, 1 mMDTT, protease in-
hibitor) on ice for 15 min and centrifuged at 14 000 × g for
10 min to clarify nuclear lysates. One milliliter lysates were
pre-cleared with T1-beads for 1 h at 4◦C and incubated with
2.5g of folded biotinylatedRNA (senseMeg3 or antisense
Meg3 RNA) for 2 h at 4◦C. Then the RNA–protein com-
plexes were captured by yeast tRNA (0.2 g/l) blocked
T1-beads by rotating at 4◦C for 30 min. The beads were
washed with 0.5 ml NLB buffer once and 0.5 ml RIP buffer
(20mMTris–Cl, pH 7.4, 140mMNaCl, 1mMEDTA, 0.5%
NP-40, 1 mM DTT) for 3 times, then re-suspended in 2×
Laemmli buffer and heated at 95◦C for 5 min. The retrieved
proteins were subjected to silver stain or identified by mass
spectrometry. Gel bands were digested using 1.5 g trypsin,
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dried completely in a speedvac, and resuspended with 21 l
of 0.1% formic acid pH 3.0. 5 l was injected per run us-
ing an Easy-nLC 1200 UPLC system. Samples were loaded
directly onto a 45 cm long 75m inner diameter nano capil-
lary column packedwith 1.9mC18-AQ (Dr.Maisch, Ger-
many) mated to metal emitter in-line with an Orbitrap Fu-
sion Lumos (Thermo Scientific, USA). The mass spectrom-
eter was operated in data dependent mode with the 120 000
resolution MS1 scan (AGC 4e5, Max IT 50 ms, 400–1500
m/z) in the Orbitrap followed by up to 20 MS/MS scans
with CID fragmentation in the ion trap. Dynamic exclusion
list was invoked to exclude previously sequenced peptides
for 60 s if sequenced within the last 30 s andmaximum cycle
time of 3 s was used. Peptide were isolated for fragmenta-
tion using the quadrupole (1.6 Da window). Ion-trap was
operated in Rapid mode with AGC 2e3, maximum IT of
300ms and minimum of 5000 ions. Raw files were searched
using Byonic and Sequest HT algorithms within the Pro-
teome Discoverer 2.1 suite (Thermo Scientific, USA). 10
ppm MS1 and 0.4 Da MS2 mass tolerances were specified.
Caramidomethylation of cysteine was used as fixed mod-
ification, oxidation of methionine, acetylation of protein
N-termini, conversion of glutamine to pyro-glutamate and
deamidation of asparagine were specified as dynamic mod-
ifications. Trypsin digestion with maximum of two missed
cleavages were allowed. Files searched against the Uniprot
homo sapiens database downloadedFeb 23rd, 2017 and sup-
plemented with common contaminants. Scaffold (version
Scaffold 4.8.4, Proteome Software Inc., Portland, OR) was
used to validate MS/MS based peptide and protein identi-
fications. Peptide identifications were accepted if they could
be established at >90% probability by the Scaffold Lo-
cal FDR algorithm. Protein identifications were accepted
if they could be established at >99% probability and con-
tained at least two identified peptides. Protein probabilities
were assigned by the Protein Prophet algorithm. Proteins
that contained similar peptides and could not be differenti-
ated based on MS/MS analysis alone were grouped to sat-
isfy the principles of parsimony.
Chromatin immunoprecipitation (ChIP)
HUVECs were treated with TNF- (10 ng/ml) for 3 h.
Formaldehyde was added directly to cell culture media to
a final concentration of 1% and the cells were cross-linked
for 10 min at room temperature. Cross-linked cells were
neutralized by addition of glycine to a final concentra-
tion of 0.125 M and incubated at room temperature for 5
min. Fixed cells were rinsed twice with cold 1× PBS and
scraped into 1× PBS containing Protease Inhibitor Cock-
tail (Roche). Cells were collected by centrifugation at 800
× g and resuspended in cell lysis buffer containing 10 mM
HEPES pH 7.9, 0.5% NP-40, 1.5 mMMgCl2, 10 mM KCl
and incubated on ice for 15 min. Nuclei were collected by
centrifugation at 800 × g and resuspended in nuclear lysis
buffer containing 1% SDS, 10 mM EDTA, 50 mM Tris–
HCl (pH 8.1), with protease inhibitor cocktail and the sam-
ples were sonicated using a Branson 250 Sonifier for 7 cycles
with each cycle comprising 20 s sonication at 20% power
and 1 min rest to yield an average DNA length of 500–1000
bp. Samples were then cleared by centrifuging at 14 000× g
for 15 min. 10 g of chromatin was diluted to 1 ml in ChIP
dilution buffer containing 0.01% SDS, 1.1% Triton X-100,
1.2 mM EDTA, 16.7 mM Tris–HCl, pH 8.1, 167 mMNaCl
and incubated with 4 g Isotype control IgG or PTBP3
antibody pre-coupled to 20 l of Dynabeads™ Protein G
(10003D, Invitrogen) and tumbled at 4◦C overnight. Prior
to antibody addition 1% of diluted chromatin was saved as
input. The immuno-precipitates were washed once with low
salt immune complex wash buffer containing 0.1% SDS, 1%
Triton X-100, 2 mM EDTA, 20 mM Tris–HCl, pH 8.1, 150
mMNaCl; oncewith high salt immune complexwash buffer
containing 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20
mMTris–HCl, pH 8.1, 500mMNaCl; twice with LiCl wash
buffer containing 0.25 M LiCl, 1% IGEPAL-CA630, 1%
sodium deoxycholic acid, 1 mM EDTA, 10 mM Tris–HCl,
pH 8.1; and twice with TE buffer containing 10 mM Tris–
HCl, 1 mM EDTA, pH 8.0.
Washed samples were resuspended in elution buffer con-
taining 1% SDS and 0.1 M NaHCO3 with 20 l of RNase
and incubated at 37◦C for 30 min to remove RNA. Fur-
ther, proteinase K was added to a final concentration of 0.2
mg/ml and reverse cross-linked by incubating at 62◦C for 2
h followed by incubating at 95◦C for 10 min. DNA was pu-
rified using Nucleospin columns using the manufacturer’s
protocol. The amount of DNA targets in the eluted sample
was measured by quantitative PCR using primers specifi-
cally targeting p53 binding regions for the respective genes
or negative control primers amplifying actin promoter or
chromosome 22 intergenic sequence (Supplementary Table
S7).
In situ RNA detection
HUVECs were cultured in Nunc® Lab-Tek® II Chamber
Slide™ 8-well system. In situRNA detection was performed
using RNAscope® 2.5 HD Reagent Kit-RED (Advanced
Cell Diagnostics) and RNAscope® Probe - Hs-MEG3 fol-
lowing themanufacturer’s instructions. RNAscope®Nega-
tiveControl ProbeDapB (E.Coli RNA)was used a negative
control and RNAscope® Positive Control Probe Hs-PPIB
as a positive control. For co-staining of Meg3 and PTBP3,
permeabilized cells were not treated with RNAscope® pro-
tease III. After Meg3 staining, cells were blocked with
RNase-free 5% goat serum in 1× PBS followed by the pri-
mary antibodies against PTBP3 in blocking buffer at 4◦C
for overnight. Then cells were washed and incubated with
the secondary antibodies Alexa Fluor 488-AffiniPure Don-
key Anti-Mouse IgG and DAPI at room temperature for
1 h. Stained samples were mounted with Fluoromount-G
for confocal imaging. Images were acquired using a Nikon
A1R-Ti2 live cell imaging confocal system. This system has
an integrated six-solid-state laser package (with 405, 440,
488, 514, 561 and 640 nm laser lines) and the ultra-sensitive
GaAsp hybrid 4+1 channel detector system.
Chromatin isolation by RNA purification (ChIRP)
ChIRP was done as previously described (38). Meg3 an-
tisense oligos with a 3′-Biotin-TEG modification were de-
signed and synthesized as described (39) (Supplementary
Table S7).
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Co-immunoprecipitation
Cells were washed once with ice cold 1× PBS and col-
lected in 1× PBS containing protease and phosphatase in-
hibitor cocktail (Roche). After centrifugation at 200 × g,
the cells were resuspended in RIPA lysis buffer (Thermo
Scientific). Subsequently, cell lysates were collected after
spinning at 13 000 × g for 10 min. Protein concentra-
tions were measured by using the Pierce BCAProtein Assay
Kit. After saving 1% of the immunoprecipitation volume
as input, lysates were split into two parts containing equal
amount of total protein. Protein A/G Dynabeads™ (In-
vitrogen) were incubated with IgG or specific antibody at
room temperature for 30 min. Beads coupled with antibod-
ies were cross-linked by incubating with 25 mMDMP in 0.2
M triethanolamine, pH 8.2 for 45 min. Further, the anti-
body coupled beads were incubated in 0.1M ethanolamine,
pH 8.2 for 30 min. The cross-linked antibody-bead com-
plexes were washed with 1× PBS containing 0.02% Tween-
20 and combined with the protein lysates and rotated
overnight at 4◦C. Subsequently, the immunoprecipitation
complexes were washed three times with ice cold RIPA
buffer. Immuno-precipitated proteins were eluted in elution
buffer containing 125 mM Tris–HCl, 5% SDS, 20% glyc-
erol and 0.01% Bromophenol Blue for 10 min at room tem-
perature with gentle agitation. 40 mM DTT was added to
the eluted protein and the lysates were incubated at 95◦C
for 5 min for western blot analysis. Anti-light chain-specific
horseradish peroxidase-conjugated antibodies (Jackson Im-
munoResearch) were used for detection.
Histone H3 and PTBP3 association assay
The method used for crosslinking, nuclear lysate prepara-
tion, immunoprecipitation and washing were the same as
described in the ChIP assay with the following modifica-
tions. The collected nuclear lysates were sonicated using a
Branson 250 Sonifier for 3 cycles with each cycle compris-
ing sonication for 20 s at 20% power. The immunoprecip-
itated samples using anti-histone H3 were heated in pro-
tein gel loading sample buffer containing DTT at 95◦C for 5
min and analyzed by SDS-PAGE. Anti-light chain-specific
horseradish peroxidase-conjugated antibodies (Jackson Im-
munoResearch) were used for detection.
Western blot analysis and antibodies
HUVECs were scraped and lysed in RIPA buffer that was
supplemented with protease and phosphatase inhibitors.
Cell lysates were collected after spinning at 13 000 × g for
10 min. Protein concentrations were measured by using the
Pierce BCA Protein Assay Kit. Lysates were analyzed by
SDS-PAGEusing 8%or 10% gels. Proteins were electroblot-
ted onto PVDFmembranes (Bio-Rad, Hercules, CA, USA)
and then incubated with corresponding antibodies. ECL
Plus Western blotting detection reagents (RPN2132; GE
Healthcare, Pittsburg, PA, USA) were used to visualize
proteins. ImageJ software (National Institutes of Health,
Bethesda, MD, USA) was used to analyze protein abun-
dance. Antibodies used in this study include anti-phospho-
ATM, anti-ATM, anti-phospho-ATR, anti-ATR, anti-
phospho-DNA-PK, anti-DNA-PK, anti-phospho-H2AX,
anti-H2AX, anti-GAPDH, anti-p53, anti-MDM2, anti-
p21, anti-PTBP3 and others. See Supplementary Table S7
for more information about antibodies.
Statistical analysis
Paired or unpaired Student’s t tests for single comparisons
and ANOVA followed by Bonferroni post hoc test for mul-
tiple comparisons were used to determine significant differ-
ences (P < 0.05) for data with a normal distribution. Nor-
mality was checked using the Kolmogorov–Smirnov test.
Data are reported as mean ± S.E.M.
RESULTS
Meg3 expression is induced by p53-mediated transcription
The human Meg3 gene produces 16 different transcript
variants (Supplemental Figure S1A). We found that the
transcript variants 1 and 6 of the Meg3 gene are dom-
inantly expressed in HUVECs using rapid amplification
of complementary DNA ends (Supplemental Figure S1B).
This was confirmed with a pair of primers that can am-
plify all the transcript variants followed by DNA sequenc-
ing (Supplementary Figure S1C). A subcellular fraction-
ation assay detected Meg3 predominantly in the nuclear
fraction, while GAPDH mRNA was found predominantly
in the cytoplasmic fraction (Supplementary Figure S1D).
Consistently, Meg3 in situ hybridization verified that the
majority of Meg3 is expressed in the nucleus in HUVECs
which was dramatically reduced by RNase treatment or
Meg3GapmeR-mediated knockdown (Supplementary Fig-
ure S1E).
Meg3 expression is elevated in senescent HUVECs com-
paredwith early passage cells (30), and inHUVECs exposed
to oxidative stress (40) and hypoxia (41). In this study, we
further examined Meg3 expression in response to different
stimuli and the signaling pathways that lead to Meg3 in-
duction in ECs. Doxorubicin is a chemotherapy drug that
can induceDNAdamage response including p53 activation.
Doxorubicin treatment led to the induction ofMeg3 inHU-
VECs (Figure 1A). Meg3 expression was 2.1-, 3.8- and 6.3-
fold higher in HUVECs that were treated with doxorubicin
at 0.2, 0.6 and 1M, respectively, for 12 h compared to con-
trol cells. Nutlin-3, a pharmacological inhibitor of MDM2
that is a negative regulator of p53, causes p53 accumulation
without inducing DNA damage. Meg3 expression was in-
duced by 2.4-, 3.0- and 2.7-fold after 12, 24 and 48 h, respec-
tively, of 10 M nutlin-3 treatment (Figure 1B). 100 M
palmitic acid induced Meg3 expression by 1.4-fold after 8
h and 2.7-fold after 24 h treatment (Figure 1C). To deter-
mine whether Meg3 is induced in a p53-dependent manner,
we examined Meg3 expression in HUVECs after shRNA-
mediated silencing of p53. Indeed, p53 knockdown blocked
the induction ofMeg3 by nutlin-3 (10Mfor 12 h) and dox-
orubicin (40 nM for 12 h) (Figure 1D). We also examined
Meg3 expression by in situ hybridization in HUVECs in re-
sponse to doxorubicin treatment at 0.2 M for 12 h. Meg3
expression was induced by 2.3-fold in the nucleus (Figure
1E). To determine whether theMeg3 promoter mediates the
induction of Meg3, the Meg3 promoter was cloned for lu-
ciferase reporter assay. As shown in the Supplemental Fig-
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/47/3/1505/5198489 by U
niversity of N
ebraska-Lincoln Libraries user on 02 O
ctober 2019
Nucleic Acids Research, 2019, Vol. 47, No. 3 1511
DMSO
Doxorubicin
µM0.2 0.6 1.0
F
ol
d 
ch
an
ge
qPCR Meg3A B
C
F
ol
d 
ch
an
ge
qPCR Meg3
DMSO
Nutlin-3
12h 24h 48h
F
ol
d 
ch
an
ge
qPCR Meg3
Ctl shRNA
p53 shRNA
Nutlin-3DoxDMSO
D
0
2
4
6
8
10
F
ol
d 
ch
an
ge
qPCR Meg3
BSA
Palmitic Acid
24h8h3h
*
*
*
*
*
*
*
*
*
*
0
2
4
6
8
10
0.0
0.5
1.0
1.5
2.0
0
2
4
6
8
10
E
Dox (+)
10 µm
Dox (-)
0
10
20
30
Dox (-) Dox (+)
*
N
um
be
r 
of
 r
ed
 d
ot
pe
r 
ce
ll
10 µm
Figure 1. Meg3 expression is induced by the DNA damage response in
a p53 dependent manner. (A) qPCR analysis of Meg3 expression in HU-
VECs treated with 200 nM, 600 nM and 1 Mof doxorubicin for 12 h. (B)
qPCR analysis ofMeg3 expression inHUVECs treated with 10Mnutlin-
3 for 12, 24 and 48 h. (C) qPCR analysis of Meg3 expression in HUVECs
treated with 100 M palmitic acid for 12, 24 and 48 h. (D) qPCR analysis
of Meg3 expression in HUVECs treated with doxorubicin (40 nM for 12
h) or nutlin-3 (10 M for 12 h) with or without lentiviral knockdown of
p53. (E) In situ hybridization ofMeg3 in HUVECs treated with or without
0.2 M doxorubicin for 12 h. The number of red dots per nucleus from 13
cells was counted for each condition. Data show mean ± S.E.M., n = 3
(A–D), n = 13 (E); *P < 0.05.
ure S2A, nutlin-3 treatment had no effect on Meg3 pro-
moter activity. We performed chromatin immunoprecipita-
tion (ChIP) followed by qPCR to examine the binding of
p53 at the Meg3 promoter. However, no binding of p53 at
theMeg3 promoterwas observed under both basal and dox-
orubicin conditions (Supplemental Figure S2B). The data
suggest that this ∼3.2 kb region (–2997 to +264) of the
Meg3 promoter is not likely involved in the induction of
Meg3 in response to DNA damage or p53 accumulation.
In summary, Meg3 expression is induced by DNA damage-
inducing stimuli in a p53 dependent manner through a dis-
tal p53 cis-element. These data suggest a potential role of
Meg3 in regulating the DDR and p53 signaling.
Meg3 knockdown induces DNA damage
SinceMeg3 expression is induced by activators of theDDR,
we next examined the role of Meg3 in DNA damage. DNA
double-strand breaks (DSB) are a severe form of DNA
damage, which can be detected by the neutral comet assay
Figure 2. Meg3 knockdown induces DNA damage. HUVECs were trans-
fected with control or Meg3 GapmeRs for neutral comet assay (A and
B) and western blot analysis (C). (A) Representative images of DNA tail
length and moment under basal condition and in ECs treated with 10
ng/ml TNF- for 16 h. (B) Quantification of DNA tail length and mo-
ment under basal conditions and in ECs treated with 10 ng/ml TNF- for
16 h. (C) Western blot analysis of key proteins involved in the DNA dam-
age response under basal conditions. Data showmean± S.E.M., n≥ 3; *P
< 0.05.
(42,43). An increase in DNA tail length and tail moment
represents a higher burden of DSBs. Meg3 knockdown by
10 nM GapmeRs (chemically modified antisense oligonu-
cleotides) led to 1.9- and 2.7-fold increases in tail length
and tail moment, respectively, under basal conditions (Fig-
ure 2A, B). In the presence of TNF-, both the tail length
and tail moment were increased by 1.6-fold (Figure 2A, B).
Phosphorylation of histone H2AX at serine 19 (known as
H2AX), a marker of DSB damage and repair (44–47), is
also increased by Meg3 silencing in ECs (Figure 2C). DDR
is controlled by three kinases ATM, ATR, and DNA-PK
(13), and serine 139 of H2AX can be phosphorylated by
all three kinases (48). ATM, but not DNA-PK and ATR,
is activated upon Meg3 silencing (Figure 2C). We also ex-
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/47/3/1505/5198489 by U
niversity of N
ebraska-Lincoln Libraries user on 02 O
ctober 2019
1512 Nucleic Acids Research, 2019, Vol. 47, No. 3
amined the effects of Meg3 knockdown on DNA damage
using GapmeRs at 2 nM concentration. Meg3 GapmeRs
reduced Meg3 expression by 88% at 2 nM and 94% at 10
nM compared to control GapmeRs (Supplementary Figure
S3A). Meg3 reduction by 2 nMGapmeRs resulted in a 2.4-
fold increase in tail length, 2.9-fold increase in tail moment,
1.9-fold increase in ATM phosphorylation, and 1.7-fold in-
crease in H2AX under basal conditions (Supplementary
Figure S3B, C). These data demonstrate thatMeg3 protects
DNA from damage.
Meg3 knockdown activates p53 signaling in ECs under in-
flammatory conditions
To determine the transcriptome that is regulated by Meg3,
we performed transcriptome microarray profiling in HU-
VECs transfected with negative control or Meg3 GapmeRs
and stimulated with TNF- for 3 h.Meg3GapmeRs used in
this study have been validated by a previous study to exam-
ine the role of Meg3 in angiogenesis (30). Meg3 expression
was reduced by 94% (Supplementary Figure S3A), which is
associated with the changes of expression of 1712 genes (P-
value < 0.05, fold change > 2) (Figure 3A and Supplemen-
tary Table S1). Among these genes, 952 genes were upreg-
ulated, and 760 genes were down-regulated. KEGG path-
way analysis of up-regulated genes identified the p53 sig-
naling pathway as the most significant among seven signal-
ing pathways in HUVECs after Meg3 silencing (Figure 3B
and Supplementary Table S2). The genome-wide p53 bind-
ing sites and p53 target genes in ECs have not been exam-
ined. However, there are 297 p53 target genes identified in
other cell types by previous studies (49,50), and many of
them were induced by Meg3 knockdown in ECs. From 952
upregulated genes, 41 were identified as p53 target genes,
and eight were identified from 760 reduced genes (Figure
3C and Supplementary Table S3). Real-time qPCR analy-
sis confirmed that the expression of many p53 target genes
were significantly induced in ECs when Meg3 expression
was reduced (Figure 3D). Meg3 knockdown also led to the
induction of p53 target genes under basal conditions (Sup-
plementary Figure S4A). Interestingly, Meg3 knockdown
also induced the expression of TNF- at the mRNA level
(Supplementary Figure S4B).We next explored the possibil-
ity that Meg3 controls the expression of p53 target genes by
regulating p53-mediated transcription.We performed chro-
matin immunoprecipitation (ChIP) followed by qPCR to
examine p53 binding at the promoter regions of several p53
target genes in the presence or absence of Meg3 silencing.
In response to Meg3 silencing, the amount of p53 bound
to the promoters of CDKN1A, GADD45A, and MDM2
was significantly increased in ECs under basal and TNF--
treated conditions (Figure 3E). Our data suggest that Meg3
restrains the expression of a subset of p53 target genes by in-
hibiting the binding of p53 to the promoters of these genes.
To examine the effects of Meg3 knockdown on the ex-
pression of proteins, quantitative proteomic analysis was
conducted using TMT10-plex labelling followed by mass
spectrometry. TNF- treatment led to 166 differentially ex-
pressed proteins (Supplementary Table S4 sheet 1). Com-
mon NF-kB target genes including VCAM1, ICAM1,
SELE, and CCL2 were induce by 6.6-, 5.3-, 3.7- and 3.2-
fold, respectively, at the protein level. KEGG pathway anal-
ysis identified three TNF- responsive pathways including
‘TNF signaling pathway’, ‘NF-kappaB signaling pathway’,
and ‘Cell adhesion molecules’ as significantly enriched sig-
naling pathways among others, suggesting that our quanti-
tative proteomics analysis can successfully detect differen-
tially expressed proteins (Supplementary Table S4 sheet 2).
Under basal conditions (without TNF- treatment), Meg3
knockdown resulted in 209 differentially expressed proteins
(Supplementary Table S4 sheet 3). KEGG pathway analy-
sis revealed four significantly enriched signaling pathways
including: ribosome biogenesis in eukaryotes, endocytosis,
glucagon signaling pathway, biosynthesis of antibiotics, and
platelet activation (Supplementary Table S4 sheet 4). In re-
sponse to TNF-, Meg3 knockdown resulted in 269 differ-
entially expressed proteins (Figure 4A and Supplementary
Table S4 sheet 5). Among them, 100 proteins were upreg-
ulated, and 169 proteins were downregulated. Gene ontol-
ogy and pathway analysis also identified the p53 signaling
pathway as the most significantly regulated pathway inHU-
VECs after Meg3 knockdown (Figure 4B and Supplemen-
tary Table S4 sheet 6). Among 100 upregulated proteins, 12
were p53 targets; while only 4 out of 169 downregulated
proteins were p53 targets (Figure 4C and Supplementary
Table S5). Indeed, Western blot analysis verified that Meg3
silencing leads to an increase in expression of p53, MDM2,
and p21 at the protein level under both basal and TNF--
treated conditions (Figure 4D, E). The amount of p53 pro-
tein in cells is determined mainly by the rate at which it is
degraded. MDM2 binds to p53 and stimulates its ubiqui-
tination and degradation(51). We reasoned that the inter-
action between MDM2 and p53 is reduced upon Meg3 si-
lencing. Indeed, we found that after immunoprecipitation
(IP) for p53, the level of p53-associated MDM2 was signif-
icantly reduced in HUVECs transfected with Meg3 Gap-
meRs (Figure 4F). The phosphorylation of p53 at serine
15 resulting from DNA damage attenuates the interaction
between p53 and MDM2, which leads to the accumula-
tion of p53 (52). We examined the phosphorylation of p53
at serine 15 in HUVECs and found that Meg3 depletion
led to an increase of the phosphorylated p53 at serine 15
(Figure 4G). We also generated lentiviral shRNA to knock-
down Meg3 expression. Consistent with Meg3 silencing by
GapmeRs, lentiviral Meg3 shRNA induced the expression
of p53 target genes, which is associated with a 56% reduc-
tion of Meg3 in HUVECs (Supplementary Figure S4C, D).
Both our transcriptomic and proteomic analysis revealed
that p53 signaling is one of the dominant signaling path-
ways upregulated byMeg3 knockdown, suggesting that en-
dogenous Meg3 restrains p53 activation in HUVECs.
In response to DNA damage, ATM is activated to phos-
phorylate a range of downstream protein substrates to con-
trol and fine-tune a complex signaling network (14). We
examined the effects of ATM inhibition or depletion on
p53 signaling and its target gene expression that are regu-
lated by Meg3. Consistent with our finding that p53 signal-
ing is the dominant signaling pathway regulated by Meg3,
p53 depletion completely blocked the induction of p53 tar-
get genes upon Meg3 knockdown (Supplementary Figure
S5A). In contrast, ATM depletion did not have the block-
ing effects (SupplementaryFigure S5B). Consistent with the
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Figure 3. Transcriptome analysis identifies p53 signaling as the most significantly upregulated pathway upon Meg3 knockdown. HUVECs were trans-
fected with control or Meg3 GapmeRs. 24 h after transfection, cells were treated with 10 ng/ml TNF- for 3 h and collected for microarray gene chip
analysis. Chromatin immunoprecipitation was performed using transfected cells with or without 10 ng/ml TNF- treatment for 1 h. (A) Volcano plot
shows differentially expressed mRNAs in ECs upon Meg3 knockdown. (B) KEGG signaling pathways analysis identified significantly regulated pathways
among upregulated genes upon Meg3 knockdown. (C) Venn diagram shows p53 target genes that are regulated by Meg3. (D) qPCR analysis of a group
of p53 target genes that were induced upon Meg3 knockdown. (E) Enrichment of p53 at the promoters of indicated genes was identified by chromatin
immunoprecipitation using anti-p53 antibodies followed by qPCR analysis. Data show mean ± S.E.M., n = 3; *P < 0.05.
result, ATM inhibition by ATM inhibitor KU-55933 did
not attenuate the increase in p53 expression and the level of
H2AX resulted from Meg3 knockdown (Supplementary
Figure S5C). These data suggest that the effects of Meg3
knockdown on p53 and H2AX may function indepen-
dently from ATM signaling (13,14).
Meg3 knockdown promotes EC apoptosis and inhibits EC
proliferation
Transcription factor p53 is a key player in cellular responses
to DNA damage and pathological stress, and its activation
leads to cell-cycle arrest and apoptosis (15,53–55). We ex-
amined the effects of Meg3 knockdown on EC apoptosis
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Figure 4. Quantitative proteomics analysis identifies p53 signaling as the most significantly regulated pathway uponMeg3 silencing. HUVECs were trans-
fected with control or Meg3 GapmeRs. 24 h after transfection, cells were treated with or without 10 ng/ml TNF- for 4 h. After treatment, cells were
collected for TMT10-plex labeling and mass spectrometry analysis, western blot analysis, or immunoprecipitation. (A) Volcano plot shows differentially
expressed proteins in ECs upon Meg3 silencing under TNF--treated condition. (B) KEGG signaling pathways were identified with significant enrich-
ment among upregulated proteins upon Meg3 silencing under TNF--treated condition. (C) Venn diagram shows proteins encoded by p53 target genes
that are regulated by Meg3 under TNF--treated condition. (D) Western blot analysis of p53, MDM2, and p21. (E) Quantifications for (D). (F) Co-
immunoprecipitation was performed to examine the interaction between p53 and MDM2 in TNF--treated HUVECs. (G) The level of phosphorylated
p53 at serine 15 was examined in immunoprecipitated total p53 in TNF--treated HUVECs transfected with control or Meg3 GapmeRs. Data show mean
± S.E.M., n = 3; *P < 0.05.
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and proliferation. Meg3 knockdown increased the activi-
ties of caspase-3/7 by 94% and 30% in ECs under basal
and TNF--treated conditions, respectively, compared to
control cells, indicating increased apoptosis resulted from
Meg3 knockdown (Figure 5A). Cell apoptosis was also ex-
amined by TdT-mediated dUTP nick end labelling assay
(TUNEL). The numbers of TUNEL-positive cells increased
by 6.6- and 1.4-fold in HUVECs with Meg3 knockdown
(Figure 5B). Since we found Meg3 deficiency induced the
expression of p21, which is an important mediator of cell-
cycle arrest induced by p53 (56,57), we reasoned that the
Meg3 knockdownmay inhibit cell proliferation. Indeed, the
number of proliferating cells were reduced by 37% (basal)
and 33% (TNF-) in ECs by Meg3 knockdown revealed by
EdU incorporation (Figure 5C). To assess whether Meg3
knockdown has any effect on the phases of cell cycle, we
performed flow cytometric analysis of cell cycle. In accor-
dance with the inductive effect on p53 expression, HUVECs
transfected with Meg3 GapmeRs had an increased popu-
lation of cells in G1 phase (Meg3 knockdown versus con-
trol: 80.3± 0.3% versus 73.4± 1.8%), a decreased popu-
lation of cells in S phage (Meg3 knockdown versus con-
trol: 7.5± 1.0% versus 12.3± 1.9%), while the percentage of
cells in G2/M phase was not significantly changed (Meg3
knockdown versus control: 7.8± 1.0% versus 10.1± 2.1%)
(Figure 5D). One important function of ECs is to form
capillary-like structures in response to angiogenic signals
during angiogenesis which can be determined in vitro by
the Matrigel network tube formation assay. We examined
the effects of Meg3 on EC tube formation. As shown in
the Supplementary Figure S6, Meg3 knockdown impaired
EC tuber formation under both basal and TNF--treated
conditions indicating a protective role of endogenousMeg3
in endothelial function. These data demonstrate that Meg3
plays important roles in EC apoptosis and proliferation by
regulating p53 signaling.
Meg3 binds to PTBP3
LncRNAs regulate gene expression through differentmech-
anisms (20,23,58,59). LncRNAs can regulate local chro-
matin structure and/or the expression of neighboring genes
in cis, or regulate cellular functions in trans after leaving
the site of transcription through the interaction with other
RNA or protein molecules (60). Meg3 silencing did not
affect the expression of Dlk1, a nearest-neighbor protein-
coding gene of Meg3 (data not shown), suggesting Meg3
likely regulates the expression of p53 target genes in trans.
First, an lncRNA pull-down assay and mass spectrome-
try were conducted to identify Meg3 binding proteins. The
RNA–protein complexes were subjected to silver staining
after separation on a gel (Figure 6A). In parallel, the RNA–
protein complexes were subjected to mass spectrometry to
identify proteins binding exclusively to sense Meg3 RNAs
compared with antisense Meg3 RNAs (Supplementary Ta-
ble S6). Polypyrimidine Tract Binding protein 3 (PTBP3)
was identified as a newMeg3 binding partner. Western blot
analysis confirmed the enrichment of PTBP3 in the RNA–
protein complexes pulled-down by sense Meg3 RNAs (Fig-
ure 6B). To explore the interaction between PTBP3 and
Meg3, we conducted a lncRNA pull-down assay using
Meg3 deletion mutants followed by western blot analysis of
PTBP3. This analysis revealed that the region encompass-
ingMeg3 441–1024 nucleotides is critical for the interaction
between Meg3 and PTBP3 (Figure 6B). To confirm the in-
teraction of endogenous Meg3 and PTBP3, we performed
RNA immunoprecipitation, and found robust enrichment
of Meg3 in the PTBP3-interacting RNA fraction compared
to IgG control (Figure 6C). A well-documented PTBP3 in-
teracting lncRNA, NEAT1 (61), was included as a positive
control and it was enriched by PTBP3RNA immunoprecip-
itation (Figure 6C).We identified thatMeg3 transcript vari-
ants 1 and 6 are highly expressed in HUVECs (Supplemen-
tal Figure S1B, C). The sequence inMeg3 transcript variant
1 (936–1049 nucleotide region) encoded by exon 4 is differ-
ent from that in Meg3 transcript variant 6. The interaction
of PTBP3with twoMeg3 transcript variants were examined
using seven different primer pairs by RNA immunoprecip-
itation. Both transcript variants were enriched in RNA im-
munoprecipitation using PTBP3 antibodies (Figure 6D).
Partial colocalization of Meg3 and PTBP3 was observed
in HUVECs by dual-staining (Figure 6E). Meg3 knock-
down did not change PTBP3 expression (Supplemental Fig-
ure S7A). PTBP3 was highly expressed in the nucleus, and
its expression and distribution were not changed by Meg3
depletion and in response to different stimuli (Supplemen-
tary Figure S7B, C). PTBP3 knockdown had no effect on
the levels of total p53, phosphorylated p53 at serine 15, and
acetylated p53 at lysine 382 inwhole lysates (Supplementary
Figure S7D). Interestingly, we observed that PTBP3was im-
munoprecipitated by anti-histone H3 antibodies, suggest-
ing an interaction between PTBP3 and chromatin (Sup-
plementary Figure S7E). However, the interaction was not
affected by Meg3 depletion or doxorubicin treatment at
the whole chromatin level (Supplementary Figure S7E). A
few proteins have been identified as Meg3 binding part-
ners previously, including p53 and PTBP1 (28,29). PTBP1
was indeed one of the top-ranked proteins identified by our
lncRNA pull-down and mass spectrometry (Supplemen-
tary Table S6). However, p53 was neither identified by pro-
teomics (Supplementary Table S6) nor western blot analysis
following lncRNA pull-down in HUVECs (Supplementary
Figure S8A). In contrast, a smaller fraction of Meg3 was
detected by p53 RNA immunoprecipitation (Supplemen-
tary Figure S8B). LncRNA DINOL was used as a positive
control which has been identified as a p53 binding partner
(62). Taken together, the in vitro and in vivo binding experi-
ments demonstrate that PTBP3 is a protein binding partner
of Meg3 in ECs.
PTBP3 silencing activates p53 signaling, promotes EC apop-
tosis, and inhibits EC proliferation
PTBP3 is a RNA binding protein, and its function is poorly
understood (63). To examine if PTBP3 mediates the effects
of Meg3 in ECs, we first examined the effects of siRNA-
mediated PTBP3 silencing on the expression of p53 tar-
get genes. PTBP3 expression was reduced by 87.7% at the
mRNA level (Figure 7A), which is associatedwith increased
expression of p53 target genes as indicated in Figure 7B. In-
terestingly, we found that Meg3 expression was increased
by PTBP3 knockdown (Figure 7A). Caspase3/7 activities
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Figure 5. Meg3 knockdown promotes apoptosis and inhibits proliferation in ECs. HUVECs were transfected with control or Meg3 GapmeRs, treated
with or without 10 ng/ml TNF- for 12 or 16 h. (A) Caspase 3/7 activities reflected by luminescence levels were measured, and fold changes were calculated
relative to that in ECs transfected with control GapmeRs without TNF- treatment. (B) The number of TUNEL positive cells per high power view were
shown. TUNEL positive cells are in red color due to presence of DNAbreaks, andDAPI-stained nuclei appear in blue. (C) The percentages of EdU positive
cells (red) among Hoechst 33342 (blue) stained cells were calculated in transfected cells with or without 12 h TNF- treatment. (D) Cell cycle distribution
revealed by flow cytometry. Data show mean ± S.E.M., n = 3; *P < 0.05.
were significantly increased upon PTBP3 knockdown un-
der basal and TNF--treated conditions (Figure 7C). The
TUNEL assay revealed that PTBP3 silencing led to a 9.8-
fold (basal) and 1.6-fold (TNF-) increase of TUNEL-
positive cells (Figure 7D). The role of PTBP3 in EC pro-
liferation was examined using the EdU incorporation assay.
The numbers of EdU-positive cells were decreased by 25.5%
and 31.9% under basal and TNF--treated conditions, re-
spectively, after PTBP3 silencing (Figure 7E). To determine
the mechanism by which PTBP3 knockdown increases the
expression of p53 target genes, we performed a ChIP assay
to examine the association of PTBP3 with the promoters of
p53 target genes. PTBP3 can bind to the promoters of p53
target genes including CDKN1A, GADD45a, and RRAD
in a Meg3-dependent manner (Figure 7F), suggesting that
PTBP3 could function as a regulator that restrains p53 ac-
tivation. Interestingly, we found that p53 knockdown has
no effect on the binding of PTBP3 at the promoters of p53
target genes including CDKN1A, GADD45a, and RRAD
(Figure 7G). Chromatin isolation by RNA purification re-
vealed the interaction of Meg3 with the promoters of p53
target genes, including CDKN1A, GADD45a, and MDM2
(Figure 7H). Since PTBP1 was identified as aMeg3 binding
partner (29), we also examined whether PTBP1 is involved
in mediatingMeg3′s effects. PTBP1 expression was reduced
by 83.4% and 82.8% under basal and TNF--treated con-
ditions, respectively (Supplementary Figure S9A). PTBP1
knockdown did not induce the expression of p53 target
genes except CMBL which was induced by 37% (Supple-
mentary Figure S9B) and did not affect EC proliferation
in EdU incorporation assay (Supplementary Figure S9C).
PTBP1 knockdown reduced caspase3/7 activities suggest-
ing that PTBP1 reduction inhibits EC apoptosis (Supple-
mentary Figure S9D). Our data demonstrate that PTBP3
rather than PTBP1 knockdown recapitulates the effects of
Meg3 knockdown on EC p53 signaling, apoptosis, and pro-
liferation, suggesting that Meg3 and PTBP3 play an impor-
tant role in regulating p53 signaling and endothelial func-
tion (Figure 8).
DISCUSSION
In this study, we examined the role of Meg3 in regulating
endothelial function through p53 signaling one of the ma-
jor coordinators of theDDR (14,64). Previous studies using
other cell types indicate that Meg3 displays positive, neg-
ative, or no effects on p53 signaling. For example, Meg3
overexpression induces the expression of p53 and its target
genes in cancer cells leading to the inhibition of cell prolif-
eration (25). In mouse neurons, Meg3 interacts with p53,
and its overexpression induces p53 and enhances its tran-
scription activity resulting in an increase in cell death (28).
However, the role of endogenousMeg3was not examined in
both these studies. In a recent study (26),Meg3was found to
interact with p53 in mouse cardiac fibroblasts.While inhibi-
tion of endogenous Meg3 reduced the expression of matrix
metalloproteinase-2 through the inhibition of p53 binding
at its promoter, there was no effect on cell apoptosis or pro-
liferation (26). In osteosarcoma tumor cells, Meg3 silenc-
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Figure 6. LncRNA pull-down assay identifies PTBP3 as a binding partner of Meg3. (A) LncRNA pull-down assay was used to identify the proteins
associatedwithMeg3 transcript variant 1 (TV1) by incubating the cell lysates with biotinylated sense or antisenseMeg3RNA. TheRNA–protein complexes
captured by T-1 beads were subjected to silver stain after separation on SDS-PAGE gel. (B) The RNA–protein complexes from lncRNA pulldown using
antisense Meg3 (negative control RNA), sense Meg3 (TV1), and Meg3 deletion mutants were subjected to western blot analysis of PTBP3 and GAPDH
after separation on SDS-PAGEgel.GAPDHwas examined as a negative control protein. (C) The interaction of endogenous PTBP3withMeg3was detected
by RNA immunoprecipitation. EC lysates were immunoprecipitated with anti-PTBP3 antibody or Isotype matched control IgG. Meg3 was examined by
qPCR in the immuno-precipitates using primer set 2 as shown in (D). LncRNA Neat1 was used as a positive control RNA that interacts with PTBP3. (D)
Different sets of Meg3 primers were used to detect Meg3 by qPCR following RNA immunoprecipitation using anti-PTBP3 antibodies. Primer sets 1, 2, 5
detect Meg3 transcript variants 1 and 6 (TV1 and TV6); primer sets 3 and 4 detect Meg3 TV1; and primer sets 6 and 7 detect Meg3 TV6. (E) Dual-staining
of Meg3 and PTBP3 in HUVECs. Linear trajectories (yellow line) crossing the cells with the intensities of Meg3 and PTBP3 signals were presented at the
right side of images. White and black arrows indicate partial colocalization of Meg3 and PTBP3 in the nucleus of HUVECs. Data show mean ± S.E.M.,
n = 3; *P < 0.05.
ing suppressed cell growth and promoted apoptosis (65).
Because of the divergent effects of Meg3 on p53 in specific
cell types, it is important to identify the molecular basis by
whichMeg3 controls p53 signaling in ECs. Our global tran-
scriptomic and proteomic analysis revealed that p53 signal-
ing is the most significantly upregulated signaling pathway
upon Meg3 silencing (Figures 3 and 4). This is not due to
off-target effects of Meg3 GapmeRs because Meg3 knock-
down mediated by lentiviral Meg3 shRNA also activates
p53 signaling (Supplementary Figure S4C, D). Our data
suggest that endogenous Meg3 restrains p53 activation in
response to inflammatory stimuli in ECs.
Meg3 is a DNA damage-responsive gene (Figure 1), and
its expression is induced in a p53-dependentmanner (Figure
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Figure 7. PTBP3 knockdown phenocopies Meg3′s effects on EC apoptosis and proliferation. HUVECs were transfected with control or PTBP3 siRNAs
(A–E), treated with or without TNF- for 12 or 16 h. HUVECs were transfected with control GapmeRs or Meg3 GapmeRs (F). (A) PTBP3 knockdown
by siRNA significantly reduces PTBP3 mRNA. (B) qPCR analysis of a group of p53 target genes in TNF--treated HUVECs. (C) Caspase 3/7 activ-
ities reflected by luminescence levels were measured, and fold changes were calculated relative to that in ECs transfected with control siRNAs without
TNF- treatment. (D) The number of TUNEL positive cells per high power view were shown. TUNEL positive cells are in red color due to presence of
DNA breaks, and DAPI-stained nuclei appear in blue. (E) The percentages of EdU positive cells (red) among Hoechst 33342 (blue) stained cells were
calculated in transfected cells with or without 12 h TNF- treatment. (F) Enrichment of PTBP3 at the promoters of indicated genes was identified by chro-
matin immunoprecipitation using anti-PTBP3 antibodies followed by qPCR analysis in TNF--treated HUVECs transfected with Ctl GapmeRs or Meg3
GapmeRs. (G) Enrichment of PTBP3 at the promoters of indicated genes was identified by chromatin immunoprecipitation using anti-PTBP3 antibodies
followed by qPCR analysis in TNF--treated HUVECs transduced with lentivirus expressing Ctl shRNA or p53 shRNA. N.S., non-significant. (H) qPCR
analysis of CDKN1A,MDM2, and GADD45a promoters after chromatin isolation by RNA purification using control probes or Meg3 probes. Data show
mean ± S.E.M., n = 3 or 4 (A–G) or = 2 (H); *P < 0.05.
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Figure 8. Schematic summary of this study. Under basal conditions, Meg3 protects DNA from damage independent of PTBP3, while it restrains the
expression of p53 target genes in cooperation with PTBP3 likely through interactions with the promoters of p53 target genes. DNA damage induces Meg3
expression via a p53 dependent mechanism. Induced Meg3 is likely involved in restoring the homeostasis of DNA damage response through an unknown
mechanism, as indicated by a question mark. Meg3 knockdown leads to DNA damage and ATM activation, which in turn stabilizes p53 by disrupting
p53 and MDM2 interaction. Activation of p53 signaling results in the expression of p53 target genes, EC apoptosis, and decreased EC proliferation.
PTBP3 knockdown phenocopies Meg3′s effects on the activation of p53 signaling, the expression of p53 target genes, EC apoptosis, and decreased EC
proliferation.
1D). Allen et al. demonstrated that p53 binding sites can be
within 50 kb downstream or upstream of the transcription
start sites of p53 direct target genes (49). Although we have
not identified the cis-element that mediates the induction of
Meg3 by p53 (Supplementary Figure S2), our data suggest
that Meg3 induction is mediated by the binding of p53 to
the distal cis-elements.
We found that Meg3 silencing induces p53 expression
at the protein level (Figure 4D). This is very likely due to
the activation of ATM (14) (Figure 2C). There are several
potential mechanisms for p53 induction in the presence of
Meg3 deficiency: (i) post-translational modification of ei-
ther Mdm2 or p53. Mdm2 is a negative regulator of p53
expression by binding to p53 and stimulating its ubiquitina-
tion and degradation (51), an effect that can be blocked by
the post-translational modification of either p53 orMDM2
(66–68); (ii) sequestration of Mdm2 by other proteins in-
cluding ribosomal protein L-5 or L-11 (RPL-5/11) (69) or
CDKN2A/ARF (70) resulting in stabilization of p53; or
(iii) an increased rate in p53 synthesis. For example, the as-
sociation of p53 mRNA with ribosome or ribosome pro-
teins such as ribosomal protein L-26 (RPL-26) can increase
the translation of p53 mRNA (71). Among these three po-
tential mechanisms, we found that the interaction between
p53 and MDM2 is markedly reduced while the phospho-
rylation of p53 at serine 15 is increased by Meg3 silencing
(Figure 4F, G), thereby highlighting that post-translational
modifications is likely having a dominant role.
PTBP3 is an RNA-binding protein, and its function re-
mains largely unknown (63). A recent study reported that
inhibition of PTBP3 induced apoptosis and cell cycle ar-
rest in tumor cells (72). We found that PTBP3 knockdown
induced the expression of p53 target genes as indicated in
Figure 7B. PTBP3 silencing also led to increased apopto-
sis and decreased cell proliferation (Figure 7C–E). PUMA
and NOXA are effectors of p53 signaling that contribute to
p53 induced-apoptosis (73). However, deletion of these p53
effectors cannot fully recapitulate the effects of loss of p53
(73), suggesting that other effectors are involved. It remains
unknown what effectors contribute to the effects of Meg3
or PTBP3 silencing on cell proliferation and apoptosis.
We found thatMeg3 controls p53 signaling under inflam-
matory states by regulating p53 binding at the promoters of
several p53 target genes (Figure 3E). There are two possibil-
ities for how the interaction of Meg3 and PTBP3 regulate
the association of p53 with its binding sites. First, Meg3
is potentially recruited to the regulatory cis-element(s) of
these genes in cooperation with PTBP3 that maintains a re-
pressed chromatin state (Figure 8). Indeed, it was reported
thatMeg3 can directly interact with regulatory sequences of
many genes (39). Second, the Meg3 and PTBP3 interaction
potentially sequesters p53 from binding to the promoters of
a subset of genes. Since Meg3 can interact with p53 directly
(25,26,28), it is possible that the interaction between Meg3
and p53 could competitively prevent the binding of p53 to
the promoters of these p53-regulated genes, although this
mechanism itself cannot explain the selective induction of
p53-regulated genes upon Meg3 or PTBP3 silencing. Fur-
thermore, we found that Meg3 has a very week interaction
with p53 in ECs (Supplementary Figure S8). BecauseMeg3
cooperates with PTBP3 to restrain p53 activation, PTBP3
could restrain p53 activation through an unknown mecha-
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nism. Indeed, we found that PTBP3 binds to the promoters
of p53 target genes in a Meg3-dependent manner (Figure
7F).
It has been reported that Meg3 binds to EZH2 and
JARID2 (39,74,75). The histonemethyltransferase EZH2 is
a core subunit of the polycomb repressive complex 2 (PRC2)
that can trimethylate histone H3 lysine 27 (H3K27) and
lead to a repressive chromatin state coinciding with gene si-
lencing (76). JARID2 is an accessory component of PRC2.
JARID2 can recruit PRC2 complexes to a heterologous
promoter, thereby increasing H3K27 trimethylation levels
on target genes, which in turn decreases gene expression
(77). Indeed, we can detect the interactions of Meg3 with
JARID2 (not EZH2) in lncRNA pull-down assays (data
not shown). This raises the possibility that Meg3 could re-
cruit PRC2 via JARID2 to specific genomic loci to restrain
gene expression in ECs by introducing repressive chromatin
modification such as H3K27 trimethylation. Future inves-
tigation will be required to explore howMeg3 regulates en-
dothelial cell responses through these multiple non-p53 de-
pendent pathways.
In summary, we demonstrated thatMeg3 cooperates with
PTBP3 to control the DNA damage response thereby pro-
tecting endothelial function. We found that Meg3 restrains
p53 activation in response to inflammatory stimuli, which
is not observed in other cell types or contrary to its role in
cancer cells and neurons. Our data highlight the possibil-
ity that a change in endothelial Meg3 expression may con-
tribute to endothelial dysfunction related to cardiovascular
disease and obesity. These data suggest that therapeutic in-
terventions that maintain Meg3 expression in the vascular
endothelium may provide opportunities for preventing en-
dothelial DNA damage and vascular dysfunction without
compromising the beneficial effects of p53 signaling in other
cell types such as in cancer (78).
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